Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Heather L Gelhorn, Beatrice Osumili, Katelyn Brown, Melissa M Ross, Andrea Schulz, Gabriela Fernandez & Kristina S Boye. (2023) The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient Preference and Adherence 17, pages 793-805.
Read now
Read now
Bidur Banjara, Nabin Poudel, Kimberly B Garza, Salisa Westrick, Heather P Whitley, David Redden & Surachat Ngorsuraches. (2022) Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Patient Preference and Adherence 16, pages 3415-3428.
Read now
Read now
Tracy J Sims, Kristina S Boye, Susan Robinson & Tessa Kennedy-Martin. (2022) Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors. Patient Preference and Adherence 16, pages 1919-1939.
Read now
Read now
Heather L Gelhorn, Kristina S Boye, Huda Shalhoub, Louis S Matza, Jessica B Jordan, Ali Alhammad, Savita B Anand, Aishah A Ekhzaimy & Alena Strizek. (2020) Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia. Patient Preference and Adherence 14, pages 2231-2242.
Read now
Read now
Thorsten Otto, Melissa Myland, Heike Jung, Jeremie Lebrec, Hartmut Richter & Kirsi Norrbacka. (2019) Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Current Medical Research and Opinion 35:5, pages 893-901.
Read now
Read now
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella & Antonella Corcos. (2018) Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Preference and Adherence 12, pages 707-719.
Read now
Read now
Louis S. Matza, Kristina S. Boye, Brooke M. Currie, Rosirene Paczkowski, Laura F. Lando, Reema Mody & Jessica Jordan. (2018) Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Current Medical Research and Opinion 34:8, pages 1457-1464.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Heather L Gelhorn, Elizabeth D Bacci, Jiat Ling Poon, Kristina S Boye, Shuichi Suzuki & Steven M Babineaux. (2016) Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan. Patient Preference and Adherence 10, pages 1337-1348.
Read now
Read now
Articles from other publishers (30)
Jaein Seo, Sebastian Heidenreich, Esraa Aldalooj, Jiat Ling Poon, Erik Spaepen, Elizabeth L. Eby & Rachel S. Newson. (2022) Patients’ Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Patients with Type 1 and Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 16:2, pages 127-138.
Crossref
Crossref
Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, Robin Wyn & Martina Smith. (2022) Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. Advances in Therapy 39:9, pages 4114-4130.
Crossref
Crossref
Ayman A. Al Hayek & Mohamed A. Al Dawish. (2022) Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study. Advances in Therapy 39:4, pages 1582-1595.
Crossref
Crossref
Erin R. Weeda, Alyssa K. Muraoka, Matthew D. Brock & Jessica M. Cannon. (2021) Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis. International Journal of Clinical Practice 75:9.
Crossref
Crossref
Kevin Fernando, Stephen C. Bain, Patrick Holmes, Philip Newland Jones & Dipesh C. Patel. (2021) Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review. Diabetes Therapy 12:9, pages 2267-2288.
Crossref
Crossref
Kristina S. Boye, Jessica B. Jordan, Raleigh E. Malik, Brooke M. Currie & Louis S. Matza. (2021) Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. Diabetes Therapy 12:9, pages 2387-2403.
Crossref
Crossref
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, Kristina Boye, Jeremie Lebrec, Myriam Rosilio, Mitch DeKoven & Bruno Guerci. (2021) Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Diabetes Therapy 12:5, pages 1553-1567.
Crossref
Crossref
Kirsi Norrbacka, Antoni Sicras-Mainar, Jeremie Lebrec, Esther Artime, Silvia Díaz, Santiago Tofé-Povedano, Ignacio Hernández & Irene Romera. (2021) Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Therapy 12:5, pages 1535-1551.
Crossref
Crossref
Akshay B. Jain, Amar Ali, Juan J. Gorgojo Martínez, Irene Hramiak, Ketan Kavia, Sten Madsbad, Louis Potier, Ben D. Prohaska, Jodi L. Strong & Tina Vilsbøll. (2020) Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice 75:2.
Crossref
Crossref
Ataru Igarashi, Brian Bekker Hansen, Jakob Langer, Francesca Tavella, Hannah Collings, Neil Davies & Robin Wyn. (2020) Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. Advances in Therapy 38:1, pages 721-738.
Crossref
Crossref
Stefano Del Prato, Jahoon Kang, Michael E. Trautmann, John Stewart, Christopher H. Sorli, Michael Derwahl, Alfonso Soto & Kun‐Ho Yoon. (2020) Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study. Diabetes, Obesity and Metabolism 22:7, pages 1176-1186.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref
Louis S. Matza, Beatrice Osumili, Katie D. Stewart, Magaly Perez-Nieves, Jessica Jordan, Giovanni Biricolti, Ester Romoli, Serena Losi, Silvia Del Santo, Erik Spaepen, Gordon Parola, Hayley Karn & Kristina S. Boye. (2019) Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy. Diabetes Therapy 11:1, pages 319-330.
Crossref
Crossref
B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Crossref
Victoria Divino, Kristina S. Boye, Jeremie Lebrec, Mitch DeKoven & Kirsi Norrbacka. (2019) GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. Diabetes Therapy 10:3, pages 1067-1088.
Crossref
Crossref
Reema Mody, Qing Huang, Maria Yu, Ruizhi Zhao, Hiren Patel, Michael Grabner & Laura Fernández Landó. (2019) Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States. Diabetes, Obesity and Metabolism 21:4, pages 920-929.
Crossref
Crossref
Anne Brooks, Jakob Langer, Tommi Tervonen, Mads Peter Hemmingsen, Kosei Eguchi & Elizabeth Dansie Bacci. (2019) Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. Diabetes Therapy 10:2, pages 735-749.
Crossref
Crossref
Giulio Marchesini, Patrizio Pasqualetti, Roberto Anichini, Salvatore Caputo, Giuseppe Memoli, Paola Ponzani, Veronica Resi, Manfredi Rizzo, Gaetano Serviddio & Giorgio Zanette. (2018) Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Acta Diabetologica 56:3, pages 289-299.
Crossref
Crossref
Vikas Soekhai, Esther W. de Bekker-Grob, Alan R. Ellis & Caroline M. Vass. (2018) Discrete Choice Experiments in Health Economics: Past, Present and Future. PharmacoEconomics 37:2, pages 201-226.
Crossref
Crossref
Raffaella Gentilella, Valeria Pechtner, Antonella Corcos & Agostino Consoli. (2019) Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes/Metabolism Research and Reviews 35:1, pages e3070.
Crossref
Crossref
Anna Y. Zhou & Jennifer M. Trujillo. (2018) Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices. Diabetes Spectrum 31:4, pages 359-366.
Crossref
Crossref
Tommi Tervonen, Tabea Schmidt-Ott, Kevin Marsh, John F.P. Bridges, Matthew Quaife & Ellen Janssen. (2018) Assessing Rationality in Discrete Choice Experiments in Health: An Investigation into the Use of Dominance Tests. Value in Health 21:10, pages 1192-1197.
Crossref
Crossref
Yehuda HandelsmanKathleen WyneAnthony CannonMichael ShannonDoron Schneider. (2018) Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S14-S29.
Crossref
Crossref
Hitoshi Ishii, Hiroki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri & Yasuhiro Akai. (2018) Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Therapy 9:3, pages 1001-1019.
Crossref
Crossref
G. Reach, V. Pechtner, R. Gentilella, A. Corcos & A. Ceriello. (2017) Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes & Metabolism 43:6, pages 501-511.
Crossref
Crossref
Gagik R. Galstyan, Evgeniya A. Karataeva & Ekaterina A. Yudovich. (2017) Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes mellitus 20:4, pages 286-298.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy 8:2, pages 335-353.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy 8:2, pages 321-334.
Crossref
Crossref
Yoshio Sumida, Yuya Seko & Masashi Yoneda. (2017) Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research 47:4, pages 266-280.
Crossref
Crossref
Ellen M. Janssen, Jodi B. Segal & John F. P. Bridges. (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 9:5, pages 465-479.
Crossref
Crossref